Fernanda Orsi: The Growing Impact of Hematology Research in Latin America
Fernanda Orsi, Associate Professor at Faculty of Medical Sciences, Unicamp, shared a post on LinkedIn:
“I’m happy to have the opportunity to participate again as a faculty member in the American Society of Hematology’s Clinical Research Training Institute in Latin America.
The course took place from May 3-6 in Bogotá, Colombia.
Once again, we had an intensive four-day course on clinical research, covering everything from introductory concepts to advanced workshops.
This year, I spoke about writing academic proposals and papers, as well as Blood Global Hematology.
As always, the most valuable sessions were the one-on-one and mentorship sessions.
Particularly, a main plus this year was the amazing networking. It was a pleasure to meet, reconnect and make friends with trainees and researchers from all over the Americas.
Above all, I’m grateful to see how research proposals from Latin America have improved in recent years.
The more I teach, the more I learn from all the participants.”

Other posts featuring Fernanda Orsi on Hemostasis Today.
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation
-
Oct 9, 2026, 15:27Mohamed Hegazi: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 9, 2026, 15:15Maha Othman: Uncovering the Consensus on TXA in TBI – Call for Collaboration on a Landmark Umbrella Review
-
Oct 9, 2026, 15:07Daniel D. Han: How Inhalation Product Exposure Impairs Cardiac and Platelet Recovery After MI
-
Oct 9, 2026, 14:58William Toole: How Ultrasound-Guided PRP Therapy Relieves Joint and Tendon Pain
-
Oct 9, 2026, 14:50Shayan Mohammadmoradi: In Corpus Christi for the 20th Midwest Platelet Conference
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning